RxDoctor Payments Data

Juan Pereda, MD

Vascular Surgery · South Miami, FLNPI 1558551135

Payments from drug & device makers

$12,959in general payments, 2019–2025

Across 278 payments — averaging $46.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Silk Road Medical, Inc.$2K
  • Organogenesis Inc.$2K
  • Bolton Medical Inc$1K
  • Endologix LLC$986
  • W. L. Gore & Associates, Inc.$772
  • Medtronic$702
  • plus $5K from 37 others

What the payments were for

  • Travel & lodging$7196%
  • Food & beverage$12,09493%
  • Education$1461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,959 in reported general payments places this provider in the 65th percentile of 385 vascular surgery providers in Florida.

See all vascular surgery providers in Florida

Medicare billing

Part B allowed, 2024
$317,228
Medicare patients
376
Services billed
1,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$114,059
XareltoRivaroxaban38$46,929
Fluocinolone Acetonide37$2,155
ClopidogrelClopidogrel Bisulfate95$955
Atorvastatin Calcium71$781
Mupirocin31$235
Rosuvastatin Calcium16$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$234$114,059100 claims
Johnson & JohnsonXarelto$500$46,92938 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 385 vascular surgery providers in Florida.

Other vascular surgery in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →